Oxidative response gene polymorphisms and risk of adult brain tumors.

Abstract:

:Oxidative stress is believed to play a key role in tumor formation. Although this mechanism could be especially pertinent for brain tumors given the high oxygen consumption of the brain, very little has been published regarding brain tumor risk with respect to genes mediating oxidative stress. Using data from non-Hispanic whites in a hospital-based case-control study conducted by the National Cancer Institute between 1994 and 1998, we evaluated risk of glioma (n=362), meningioma (n=134), and acoustic neuroma (n=69) compared to noncancer controls (n=494) with respect to nine single nucleotide polymorphisms from seven genes involved in oxidative stress response (CAT, GPX1, NOS3, PON1, SOD1, SOD2, and SOD3). We observed increased risk of glioma (odds ratio [OR](CT/CC)=1.3; 95% confidence interval [95% CI], 1.0-1.7) and meningioma (OR(CT/CC)=1.7; 95% CI, 1.1-2.7) with the C variant of SOD3 rs699473. There was also indication of increased acoustic neuroma risk with the SOD2 rs4880 Ala variant (OR(CT/CC)=2.0; 95% CI, 1.0-4.2) and decreased acoustic neuroma risk with the CAT rs1001179 T allele variant (OR(CT/TT)=0.6; 95% CI, 0.3-1.0). These relationships persisted when major groups of disease controls were excluded from the analysis. Our results suggest that common variants in the SOD2, SOD3, and CAT genes may influence brain tumor risk.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Rajaraman P,Hutchinson A,Rothman N,Black PM,Fine HA,Loeffler JS,Selker RG,Shapiro WR,Linet MS,Inskip PD

doi

10.1215/15228517-2008-037

subject

Has Abstract

pub_date

2008-10-01 00:00:00

pages

709-15

issue

5

eissn

1522-8517

issn

1523-5866

pii

15228517-2008-037

journal_volume

10

pub_type

杂志文章,多中心研究
  • Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.

    abstract::Gliomas are a heterogeneous group of brain tumors with distinct biological and clinical properties. Despite advances in surgical techniques and clinical regimens, treatment of high-grade glioma remains challenging and carries dismal rates of therapeutic success and overall survival. Challenges include the molecular co...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nox183

    authors: Malta TM,de Souza CF,Sabedot TS,Silva TC,Mosella MS,Kalkanis SN,Snyder J,Castro AVB,Noushmehr H

    更新日期:2018-04-09 00:00:00

  • Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

    abstract:BACKGROUND:The Cancer Genome Atlas (TCGA) project is a large-scale effort with the goal of identifying novel molecular aberrations in glioblastoma (GBM). METHODS:Here, we describe an in-depth analysis of gene expression data and copy number aberration (CNA) data to classify GBMs into prognostic groups to determine cor...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not024

    authors: Kim YW,Koul D,Kim SH,Lucio-Eterovic AK,Freire PR,Yao J,Wang J,Almeida JS,Aldape K,Yung WK

    更新日期:2013-07-01 00:00:00

  • Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance.

    abstract:Background:Depending on the level, differentiation state, and tumor stage, reactive nitrogen and oxygen species inhibit or increase cancer growth and tumor initiating cell maintenance. The rate-limiting enzyme in a pathway that can regulate reactive species production but has not been thoroughly investigated in gliobla...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noy012

    authors: Tran AN,Walker K,Harrison DG,Chen W,Mobley J,Hocevar L,Hackney JR,Sedaka RS,Pollock JS,Goldberg MS,Hambardzumyan D,Cooper SJ,Gillespie Y,Hjelmeland AB

    更新日期:2018-07-05 00:00:00

  • Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies.

    abstract::Epidermal growth factor receptor (EGFR) gene amplification and activating mutations are common findings in glioblastomas. EGFR is at the top of a downstream signaling cascade that regulates important characteristics of glioblastoma cells, including cellular proliferation, migration, and survival. Targeting EGFR has th...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou222

    authors: Roth P,Weller M

    更新日期:2014-10-01 00:00:00

  • Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.

    abstract::The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intrav...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-043

    authors: Bradley KA,Pollack IF,Reid JM,Adamson PC,Ames MM,Vezina G,Blaney S,Ivy P,Zhou T,Krailo M,Reaman G,Mehta MP,Children's Oncology Group.

    更新日期:2008-10-01 00:00:00

  • Assessment and treatment relevance in elderly glioblastoma patients.

    abstract::Glioblastoma (GBM) is the most common malignant primary brain tumor. Its incidence continues to increase in the elderly because the older segment of the population is growing faster than any other age group. Most clinical studies exclude elderly patients, and "standards of care" do not exist for GBM patients aged >70 ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou063

    authors: Bauchet L,Zouaoui S,Darlix A,Menjot de Champfleur N,Ferreira E,Fabbro M,Kerr C,Taillandier L

    更新日期:2014-11-01 00:00:00

  • Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.

    abstract::Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly in combination with irinotecan. However, responses are rarely durable. Continuation of bevacizumab in combination with another chemotherapeutic agent may demon...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2009-006

    authors: Quant EC,Norden AD,Drappatz J,Muzikansky A,Doherty L,Lafrankie D,Ciampa A,Kesari S,Wen PY

    更新日期:2009-10-01 00:00:00

  • Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

    abstract:BACKGROUND:Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic and epigenetic alterations are undefined but nonetheless highly relevant to combinatorial treatments. METHODS:Patients with CNS ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/now132

    authors: Garber ST,Hashimoto Y,Weathers SP,Xiu J,Gatalica Z,Verhaak RG,Zhou S,Fuller GN,Khasraw M,de Groot J,Reddy SK,Spetzler D,Heimberger AB

    更新日期:2016-10-01 00:00:00

  • Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA.

    abstract:BACKGROUND:Available evidence on diet and glioma risk comes mainly from studies with retrospective collection of dietary data. To minimize possible differential dietary recall between those with and without glioma, we present findings from 3 large prospective studies. METHODS:Participants included 692 176 from the UK ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,meta分析

    doi:10.1093/neuonc/noz013

    authors: Kuan AS,Green J,Kitahara CM,De González AB,Key T,K Reeves G,Floud S,Balkwill A,Bradbury K,Liao LM,Freedman ND,Beral V,Sweetland S,Million Women Study, the NIH-AARP study, and the PLCO study.

    更新日期:2019-07-11 00:00:00

  • Memory in low-grade glioma patients treated with radiotherapy or Temozolomide. A correlative analysis of EORTC study 22033-26033.

    abstract:BACKGROUND:EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or Temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of radiotherapy on memory functioning, this stu...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa252

    authors: Klein M,Drijver AJ,van den Bent MJ,Bromberg JC,Hoang-Xuan K,Taphoorn MJB,Reijneveld JC,Ben Hassel M,Vauleon E,Eekers DBP,Tzuk-Shina T,Lucas A,Freixa SV,Golfinopoulos V,Gorlia T,Hottinger AF,Stupp R,Baumert BG

    更新日期:2020-11-01 00:00:00

  • Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway.

    abstract::Neuroblastomas, an embryonic cancer of the sympathetic nervous system, often occur in young children. Honokiol, a small-molecule polyphenol, has multiple therapeutic effects and pharmacological activities. This study was designed to evaluate whether honokiol could pass through the blood-brain barrier (BBB) and induce ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor217

    authors: Lin JW,Chen JT,Hong CY,Lin YL,Wang KT,Yao CJ,Lai GM,Chen RM

    更新日期:2012-03-01 00:00:00

  • Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors.

    abstract::In order to compare in vivo metabolism between malignant gliomas and normal brain, (13)C magnetic resonance (MR) spectroscopic imaging data were acquired from rats with human glioblastoma xenografts (U-251 MG and U-87 MG) and normal rats, following injection of hyperpolarized [1-(13)C]-pyruvate. The median signal-to-n...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nop043

    authors: Park I,Larson PE,Zierhut ML,Hu S,Bok R,Ozawa T,Kurhanewicz J,Vigneron DB,Vandenberg SR,James CD,Nelson SJ

    更新日期:2010-02-01 00:00:00

  • Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

    abstract:BACKGROUND:We recently demonstrated that brain endothelial cells and astrocytes protect cancer cells from chemotherapy through an endothelin-dependent signaling mechanism. Here, we evaluated the efficacy of macitentan, a dual endothelin receptor (ETAR and ETBR) antagonist, in the treatment of experimental breast and lu...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/now037

    authors: Lee HJ,Hanibuchi M,Kim SJ,Yu H,Kim MS,He J,Langley RR,Lehembre F,Regenass U,Fidler IJ

    更新日期:2016-04-01 00:00:00

  • Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.

    abstract:BACKGROUND:Antiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting. METHODS:Twelve patients with 20 VSs were recruited. Each had at least one rapidly gr...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov168

    authors: Li KL,Djoukhadar I,Zhu X,Zhao S,Lloyd S,McCabe M,McBain C,Evans DG,Jackson A

    更新日期:2016-02-01 00:00:00

  • A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models.

    abstract::Difficulties of drug delivery across the blood-brain barrier (BBB) and failure to eliminate cancer stem cells (CSCs) are believed to be the major causes of tumor recurrences in children with medulloblastoma (MB). Seneca Valley virus-001 (SVV-001) is a naturally occurring oncolytic picornavirus that can be systemically...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq148

    authors: Yu L,Baxter PA,Zhao X,Liu Z,Wadhwa L,Zhang Y,Su JM,Tan X,Yang J,Adesina A,Perlaky L,Hurwitz M,Idamakanti N,Police SR,Hallenbeck PL,Blaney SM,Chintagumpala M,Hurwitz RL,Li XN

    更新日期:2011-01-01 00:00:00

  • Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.

    abstract:BACKGROUND:Meningiomas are the most commonly diagnosed primary intracranial neoplasms. Despite significant advances in modern therapies, the management of malignant meningioma and skull base meningioma remains a challenge. Thus, the development of new treatment modalities is urgently needed for these difficult-to-treat...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not007

    authors: Iwami K,Natsume A,Ohno M,Ikeda H,Mineno J,Nukaya I,Okamoto S,Fujiwara H,Yasukawa M,Shiku H,Wakabayashi T

    更新日期:2013-06-01 00:00:00

  • Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

    abstract::The effects of combining histone deacetylase (HDAC) inhibitors and proteasome inhibitors were evaluated in both established glioblastoma multiforme (GBM) cell lines and short-term cultures derived from the Mayo Clinic xenograft GBM panel. Coexposure of LBH589 and bortezomib at minimally toxic doses of either drug alon...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-063

    authors: Yu C,Friday BB,Yang L,Atadja P,Wigle D,Sarkaria J,Adjei AA

    更新日期:2008-06-01 00:00:00

  • Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma.

    abstract:BACKGROUND:We report a phase I study to examine the pharmacokinetics, safety, and recommended dosage of weekly intravenous bolus 5-fluorouracil (5-FU) in children and young adults with recurrent ependymoma. METHODS:Patients 22 years of age or less with recurrent ependymoma were treated with bolus dosage 5-FU weekly fo...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nov181

    authors: Wright KD,Daryani VM,Turner DC,Onar-Thomas A,Boulos N,Orr BA,Gilbertson RJ,Stewart CF,Gajjar A

    更新日期:2015-12-01 00:00:00

  • SPARC affects glioma cell growth differently when grown on brain ECM proteins in vitro under standard versus reduced-serum stress conditions.

    abstract::Secreted protein acidic and rich in cysteine (SPARC) has a suppressive effect on U87 glioma cell proliferation when assessed in vitro and in vivo using parental U87T2 and U87T2-derived SPARC-transfected clones. Since SPARCinteracts with extracellular matrix (ECM) proteins, we examined the effect of SPARC secretion on ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/5.4.244

    authors: Vadlamuri SV,Media J,Sankey SS,Nakeff A,Divine G,Rempel SA

    更新日期:2003-10-01 00:00:00

  • Arterial spin labeling MR imaging for differentiation between high- and low-grade glioma-a meta-analysis.

    abstract:Background:Arterial spin labeling is an MR imaging technique that measures cerebral blood flow (CBF) non-invasively. The aim of the study is to assess the diagnostic performance of arterial spin labeling (ASL) MR imaging for differentiation between high-grade glioma and low-grade glioma. Methods:Cochrane Library, Emba...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,meta分析

    doi:10.1093/neuonc/noy095

    authors: Falk Delgado A,De Luca F,van Westen D,Falk Delgado A

    更新日期:2018-10-09 00:00:00

  • AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix.

    abstract::High-grade gliomas release excitotoxic concentrations of glutamate, which has been shown to enhance tumor proliferation and migration. alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors are abundantly expressed at the invading edge of glioblastoma specimens, suggesting they may play an...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2008-094

    authors: Piao Y,Lu L,de Groot J

    更新日期:2009-06-01 00:00:00

  • Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.

    abstract::The objective of this study was to ascertain the duration of tumor control and the toxicities of dose-intense myeloablative chemotherapy for patients with recurrent oligodendrogliomas. Patients with previously irradiated oligodendrogliomas, either pure or mixed, that were contrast enhancing, measurable, and behaving a...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/2.2.114

    authors: Cairncross G,Swinnen L,Bayer R,Rosenfeld S,Salzman D,Paleologos N,Kaminer L,Forsyth P,Stewart D,Peterson K,Hu W,Macdonald D,Ramsay D,Smith A,Oligodendroglioma Study Group.

    更新日期:2000-04-01 00:00:00

  • Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.

    abstract:BACKGROUND:The standard of care for newly diagnosed glioblastoma is maximal safe surgical resection, followed by chemoradiation therapy. We assessed carmustine wafer implantation efficacy and safety when used in combination with standard care. METHODS:Included were adult patients with (n = 354, implantation group) and...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1093/neuonc/nov126

    authors: Pallud J,Audureau E,Noel G,Corns R,Lechapt-Zalcman E,Duntze J,Pavlov V,Guyotat J,Hieu PD,Le Reste PJ,Faillot T,Litre CF,Desse N,Petit A,Emery E,Voirin J,Peltier J,Caire F,Vignes JR,Barat JL,Langlois O,Dezamis E

    更新日期:2015-12-01 00:00:00

  • Germline microsatellite genotypes differentiate children with medulloblastoma.

    abstract:BACKGROUND:The germline genetic events underpinning medulloblastoma (MB) initiation, and therefore the ability to determine who is at risk, are still unknown for the majority of cases. Microsatellites are short repeated sequences that make up ~3% of the genome. Repeat lengths vary among individuals and are often nonran...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz179

    authors: Rivero-Hinojosa S,Kinney N,Garner HR,Rood BR

    更新日期:2020-01-11 00:00:00

  • Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.

    abstract::The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas. Patients with stable or progressive malignant primar...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/S1522851705000451

    authors: Prados MD,Lamborn KR,Chang S,Burton E,Butowski N,Malec M,Kapadia A,Rabbitt J,Page MS,Fedoroff A,Xie D,Kelley SK

    更新日期:2006-01-01 00:00:00

  • Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells.

    abstract:INTRODUCTION:Overexpression of the Polycomb repressive complex 2 (PRC2) subunit Enhancer of Zeste 2 (EZH2) occurs in several malignancies, including prostate cancer, breast cancer, medulloblastoma, and glioblastoma multiforme. Recent evidence suggests that EZH2 may also have a role in rhabdoid tumors. Atypical teratoid...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos285

    authors: Alimova I,Birks DK,Harris PS,Knipstein JA,Venkataraman S,Marquez VE,Foreman NK,Vibhakar R

    更新日期:2013-02-01 00:00:00

  • Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007.

    abstract:BACKGROUND:Glioblastoma multiforme, a World Health Organization grade IV glioma, has a poor prognosis in humans despite current treatment options. Here, we present magnetic resonance imaging (MRI) data regarding the regression of aggressive rat F98 gliomas and human U87 glioma xenografts after treatment with the nitron...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos337

    authors: Towner RA,Gillespie DL,Schwager A,Saunders DG,Smith N,Njoku CE,Krysiak RS 3rd,Larabee C,Iqbal H,Floyd RA,Bourne DW,Abdullah O,Hsu EW,Jensen RL

    更新日期:2013-03-01 00:00:00

  • PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

    abstract::The signaling pathways that underlie the pathogenesis of pediatric gliomas are poorly understood. We characterized the PI3K/Akt/mTOR pathway in pediatric gliomas of all grades. Using immunohistochemistry, we assessed activation of the PI3K/Akt/mTOR pathway by evaluating the downstream signaling molecules phospho(p)-S6...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos140

    authors: Mueller S,Phillips J,Onar-Thomas A,Romero E,Zheng S,Wiencke JK,McBride SM,Cowdrey C,Prados MD,Weiss WA,Berger MS,Gupta N,Haas-Kogan DA

    更新日期:2012-09-01 00:00:00

  • Tailoring neurophysiological strategies with clinical context enhances resection and safety and expands indications in gliomas involving motor pathways.

    abstract:BACKGROUND:Resection of motor pathway gliomas requires the intraoperative recognition of essential cortical-subcortical motor structures. The degree of involvement of motor structures is variable, and increases as result of treatments patients are submitted to. Intraoperative neurophysiology offers various stimulation ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not327

    authors: Bello L,Riva M,Fava E,Ferpozzi V,Castellano A,Raneri F,Pessina F,Bizzi A,Falini A,Cerri G

    更新日期:2014-08-01 00:00:00

  • Molecular and translational advances in meningiomas.

    abstract::Meningiomas are the most common primary intracranial neoplasm. The current World Health Organization (WHO) classification categorizes meningiomas based on histopathological features, but emerging molecular data demonstrate the importance of genomic and epigenomic factors in the clinical behavior of these tumors. Treat...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/noy178

    authors: Suppiah S,Nassiri F,Bi WL,Dunn IF,Hanemann CO,Horbinski CM,Hashizume R,James CD,Mawrin C,Noushmehr H,Perry A,Sahm F,Sloan A,Von Deimling A,Wen PY,Aldape K,Zadeh G,International Consortium on Meningiomas.

    更新日期:2019-01-14 00:00:00